
KDNY
Healthcare · Biotechnology · $2.71B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · -4.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 7, 2023 | After the close | -0.81 | -0.94 | -16.0% |
| May 9, 2023 | After the close | -0.79 | -0.85 | -7.6% |
| Feb 27, 2023 | After the close | -0.79 | -0.90 | -13.9% |
| Nov 10, 2022 | After the close | -0.63 | -0.83 | -31.7% |
| Aug 8, 2022 | After the close | -0.61 | -0.61 | 0.0% |
| May 12, 2022 | After the close | -0.67 | -0.54 | +19.4% |
| Mar 17, 2022 | After the close | -0.68 | 0.14 | +120.6% |
| Nov 8, 2021 | Before the open | -0.84 | -0.69 | +17.9% |
| Aug 12, 2021 | After the close | -0.78 | -1.14 | -46.2% |
| Apr 7, 2021 | After the close | -0.44 | -1.24 | -181.8% |
| Nov 5, 2020 | After the close | -0.45 | -0.90 | -100.0% |
| Aug 3, 2020 | After the close | -0.95 | -1.05 | -10.5% |
| May 4, 2020 | After the close | -0.67 |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal…
| -0.45 |
| +32.8% |
| Mar 9, 2020 | After the close | -1.05 | -1.20 | -14.3% |
| Nov 7, 2019 | After the close | -1.16 | -1.00 | +13.8% |
| Aug 1, 2019 | After the close | -0.91 | -1.15 | -26.4% |
| May 7, 2019 | After the close | -0.95 | -1.45 | -52.6% |
| Feb 27, 2019 | After the close | -1.16 | -1.65 | -42.2% |
| Oct 30, 2018 | After the close | -1.56 | -1.45 | +7.1% |
| Aug 1, 2018 | After the close | -1.59 | -1.55 | +2.5% |
| May 2, 2018 | After the close | -1.75 | -1.40 | +20.0% |
| Mar 1, 2018 | After the close | -1.81 | -1.70 | +6.1% |